secwatch.observer — SEC 8-K summary
======================================

Issuer:     OS Therapies Inc (OSTX)
CIK:        0001795091
Form:       8-K
Filed at:   2025-05-16T23:59:59+00:00
Accession:  0001213900-25-044875
Event type: earnings
Sentiment:  neutral
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

OS Therapies Q1 net op loss $3.876M; OST-HER2 BLA on track for Q3 2025
----------------------------------------------------------------------

- Net operating loss of $3.876M in Q1 2025 vs $1.490M in Q1 2024, due to trial closeout and regulatory prep costs.
- Net loss per share of $0.18 on 21.249M shares vs $0.25 on 5.991M shares in prior year period.
- Positive Phase 2b data for OST-HER2 in pediatric osteosarcoma; FDA Type D meeting feedback expected mid-June 2025.
- Company on track to file BLA for OST-HER2 in Q3 2025 for accelerated approval in osteosarcoma.
- Acquired three clinical-stage and eight preclinical listeria immunotherapy assets from Ayala Pharmaceuticals.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1795091/000121390025044875/0001213900-25-044875-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1795091/000121390025044875/ea0242452-8k_ostherapies.htm
  HTML page:      https://secwatch.observer/filing/0001213900-25-044875

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer